Update and insights into treatment options for chronic spontaneous urticaria

References

• Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 2013;11(10):971-8
   PubMed Web of Science ®Google Scholar
• Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58(7):621-3
   PubMed Web of Science ®Google Scholar
• Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: a patient survey on quality-of-life, treatment usage and doctor-patient relation. Allergy 2009;64(4):581-8
   Google Scholar
• O'Donnell B, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136(2):197-201
   PubMed Web of Science ®Google Scholar
• Grob J, Revuz J, Ortonne J, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005;152(2):289-95
   PubMed Web of Science ®Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011;66(3):317-30
   PubMed Web of Science ®Google Scholar
• Delong L, Culler S, Saini S, et al. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008;144(1):35-9
   PubMedGoogle Scholar
• Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001;45(3):378-91
   Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64(10):1427-43
   PubMed Web of Science ®Google Scholar
• Leznoff A, Josse R, Denburg J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983;119(8):636-40
   PubMedGoogle Scholar
• Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009;39(6):777-87
   PubMed Web of Science ®Google Scholar
• Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012;129(5):1307-13
   PubMed Web of Science ®Google Scholar
• Tarbox JA, Gutta RC, Radojicic C, Lang DM. Utility of routine laboratory testing in management of chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2011;107(3):239-43
   PubMed Web of Science ®Google Scholar
• Weller K, Schoepke N, Krause K, et al. Selected urticaria patients benefit from a referral to tertiary care centres – results of an expert survey. J Eur Acad Dermatol Venereol 2013;27(1):e8-16
   Google Scholar
• Maurer M, Metz M, Magerl M, et al. Autoreactive urticaria and autoimmune urticaria. Hautarzt 2004;55(4):350-6
   Google Scholar
• Hakim-Rad K, Metz M, Maurer M. Mast cells: makers and breakers of allergic inflammation. Curr Opin Allergy Clin Immunol 2009;9(5):427-30
   PubMed Web of Science ®Google Scholar
• Leurs R, Church MK, Taglialatela M.H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32(4):489-98
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65(4):459-66
   PubMed Web of Science ®Google Scholar
• Boyle J, Eriksson M, Stanley N, et al. Allergy medication in Japanese volunteers: treatment effect of single doses on nocturnal sleep architecture and next day residual effects. Curr Med Res Opin 2006;22(7):1343-51
   PubMed Web of Science ®Google Scholar
• Rojas-Zamorano JA, Esqueda-Leon E, Jimenez-Anguiano A, et al. The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobilization stress in rats. Pharmacol Biochem Behav 2009;91(3):291-4
   Google Scholar
• Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351(21):2203-17
   PubMed Web of Science ®Google Scholar
• Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008;63(Suppl 87):5-28
   PubMed Web of Science ®Google Scholar
• Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria: an evidence-based review. Am J Clin Dermatol 2011;12(6):361-76
   Google Scholar
• Guerra L, Vincenzi C, Marchesi E, et al. Loratadine and cetirizine in the treatment of chronic urticaria. J Eur Acad Dermatol Venereol 1994;3(2):148-52
   Google Scholar
• Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat 2004;15(1):55-7
   PubMedGoogle Scholar
• Garg G, Thami GP. Comparative efficacy of cetirizine and levocetirizine in chronic idiopathic urticaria. J Dermatolog Treat 2007;18(1):23-4
   Web of Science ®Google Scholar
• Potter PC, Kapp A, Maurer M, et al. Comparison of the efficacy of levocetirizine 5mg and desloratadine 5mg in chronic idiopathic urticaria patients. Allergy 2009;64(4):596-604
   PubMed Web of Science ®Google Scholar
• Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to treat urticaria. J Allergy Clin Immunol 2010;125(3):676-82
   PubMed Web of Science ®Google Scholar
• Ferrer M, Sastre J, Jáuregui I, et al. Effect of antihistamine up-dosing in chronic urticaria. J Investig Allergol Clin Immunol 2011;21(Suppl 3):34-9
   PubMed Web of Science ®Google Scholar
• Weller K, Ziege C, Staubach P, et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side-effects: a retrospective survey study. PLoS One 2011;6(9):e23931
   PubMedGoogle Scholar
• Grob J, Auquier P, Dreyfus I, Ortonne J. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009;64(4):605-12
   PubMed Web of Science ®Google Scholar
• Weller K, Ardelean E, Scholz E, et al. Can on demand non sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol 2013;93(2):168-74
   PubMedGoogle Scholar
• Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110(3):484-8
   Google Scholar
• Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res 2005;297(3):134-8
   PubMed Web of Science ®Google Scholar
• Wan KS. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antagonist for treatment of chronic idiopathic urticaria. J Dermatolog Treat 2009;20(4):194-7
   Web of Science ®Google Scholar
• Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012;3:CD008596
   PubMed Web of Science ®Google Scholar
• Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2011;31(10):1607-14
   Google Scholar
• EMA. Xolair summary of product characteristics. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf
   Google Scholar
• Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99(2):190-3
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122(3):569-73
   PubMed Web of Science ®Google Scholar
• Gober LM, Sterba PM, Eckman JA, Saini SS. Effect of Anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients. J Allergy Clin Immunol 2008;121(2 Suppl 1):S147
   Google Scholar
• Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010;126(3):665-6
   PubMed Web of Science ®Google Scholar
• Groffik A, Mitzel-Kaoukhov H, Magerl M, et al. Omalizumab: an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66(2):303-5
   PubMed Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose ranging study of single-dose omalizumab in patients with H1-antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128(3):567-73
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128(1):202-9
   PubMed Web of Science ®Google Scholar
• Ferrer M, Gamboa P, Sanz M, et al. Omalizumab is effective in non-autoimmune urticaria. J Allergy Clin Immunol 2011;127(5):1300-2
   PubMed Web of Science ®Google Scholar
• Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100(1):110-21
   PubMed Web of Science ®Google Scholar
• MacGlashan D, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158(3):1438-45
   PubMed Web of Science ®Google Scholar
• MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 2004;114(6):1472-4
   Google Scholar
• Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006;117(6):1493-9
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368(10):924-35
   PubMed Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132(1):101-9
   PubMed Web of Science ®Google Scholar
• Arkwright P. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. J Allergy Clin Immunol 2009;123(2):510-11
   PubMed Web of Science ®Google Scholar
• Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol 2011;128(6):1354-5
   PubMed Web of Science ®Google Scholar
• Mallipeddi R, Grattan CE. Lack of response of severe steroid-dependent chronic urticaria to rituximab. Clin Exp Dermatol 2007;32(3):333-4
   Google Scholar
• Lenormand C, Lipsker D. Efficiency of interleukin-1 blockade in refractory delayed-pressure urticaria. Ann Intern Med 2012;157(8):599-600
   PubMed Web of Science ®Google Scholar
• Krause K, Mahamed A, Weller K, et al. Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J Allergy Clin Immunol 2013;132(3):751-4
   Google Scholar
• Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991;21(6):695-704
   PubMed Web of Science ®Google Scholar
• Hide M, Francis DM, Grattan CH, Greaves MW. Autoantibodies against the high affinity IgE receptor as a cause for histamine release in chronic urticaria. N Eng J Med 1993;328(22):1599-604
   PubMed Web of Science ®Google Scholar
• Sabroe RA, Fiebiger E, Francis DM, et al. Classification of anti-FceRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002;110(3):492-9
   PubMed Web of Science ®Google Scholar
• Grattan CEH, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000;143(2):365-72
   PubMed Web of Science ®Google Scholar
• Iqbal K, Bhargava K, Skov PS, et al. A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria. Clin Transl Allergy 2012;2(1):19
   Google Scholar
• Cirillo R, Triggiani M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 1990;144(10):3891-7
   Google Scholar
• Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992;98(5):800-4
   Google Scholar
• Casolaro V, Spadaro G, Patella V, Marone G. In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 1993;151(10):5563-73
   Google Scholar
• Marsland AM, Soundararajan S, Joseph K, Kaplan AP. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clin Exp Allergy 2005;35(5):554-9
   Web of Science ®Google Scholar
• Wershil BK, Furuta GT, Lavigne JA, et al. Dexamethasone or cyclosporin A suppresses mast cell-leukocyte cytokine cascades. Multiple mechanisms of inhibition of IgE- and mast cell-dependent cutaneous inflammation in the mouse. J Immunol 1995;154(3):1391-8
   Google Scholar
• Chapman I, Mazzoni L. Mechanisms of inhibition by cyclosporin A on pulmonary leukocyte accumulation. Trends Pharmacol Sci 1994;15(4):99-101
   Google Scholar
• Fradin MS, Ellis CN, Goldfarb MT, Voorhees JJ. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991;25(6 Pt 1):1065-7
   Google Scholar
• Barlow RJ, Black AK, Greaves MW. Treatment of severe chronic urticaria with cyclosporine-A. Eur J Dermatol 1993;3(4):273-5
   Google Scholar
• Toubi E, Blant A, Kessel A, Golan TD. Low-dose cyclosporin A in the treatment of severe chronic urticaria. Allergy 1997;52(3):312-16
   PubMedGoogle Scholar
• Vena GA, Cassano N, Colombo D, et al. Neo-I-30 study Group. Cyclosporin A in chronic idiopathic urticaria: a double blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006;55(4):705-9
   PubMed Web of Science ®Google Scholar
• Serhat Inaloz H, Ozturk S, Akcali C, et al. Low-dose and short-term cyclosporine treatment in patients with chronic urticaria: a clinical and immunological evaluation. J Dermatol 2008;35(5):276-82
   PubMed Web of Science ®Google Scholar
• Kessel A, Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010;65(11):1478-82
   PubMed Web of Science ®Google Scholar
• Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010;162(1):191-4
   PubMed Web of Science ®Google Scholar
• Shahar E, Bergman R, Guttman-Yassky E, Pollack S. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006;45(10):1224-7
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M. H. 1)-antihistamines and urticaria: how can we predict the best drug for our patient? Clin Exp Allergy 2012;42(10):1423-9
   Google Scholar
• Ferrer M, Luquin E, Sanchez-Ibarrola A, et al. Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Immunol 2002;129(3):254-60
   Google Scholar
• Leonard R, Hardy J, Van Tienhoven G, et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 2001;19(21):4150-9
   PubMed Web of Science ®Google Scholar
• Rahman M, Ahmed BN, Faiz MA, et al. Phase IV. Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala- Azar) in Bangladesh. Am J Trop Med Hyg 2011;85(1):66-9
   PubMed Web of Science ®Google Scholar
• Barratt G, Saint-Pierre-Chazalet M, Loiseau PM. Cellular transport and lipid interactions of miltefosine. Curr Drug Metab 2009;10(3):247-55
   Google Scholar
• Silveira ESAM, Mazucato VM, Jamur MC, Oliver C. Lipid rafts in mast cell biology. J Lipids 2011;2011:752906
   PubMedGoogle Scholar
• Weller K, Artuc M, Jennings G, et al. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol 2009;129(2):496-8
   Google Scholar
• Hartmann K, Siebenhaar F, Belloni B, et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2010;162(1):185-90
   Google Scholar
• Magerl M, Rother M, Bieber T, et al. Randomized, double-blind, placebo controlled study of safety and efficacy of miltefosine in antihistamine resistant chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2013;27(3):e363-9
   Google Scholar
• Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002;109(4):694-700
   PubMed Web of Science ®Google Scholar
• Puccetti A, Bason C, Simeoni S, et al. In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine via eosinophil activation. Clin Exp Allergy 2005;35(12):1599-607
   Google Scholar
• Rabelo-Filardi R, Daltro-Oliveira R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol 2013;161(3):197-204
   Google Scholar